Scarica l'app Stockscreener
142.85
1.09%
-1.57
Dopo l'orario di chiusura:
142.40
-0.45
-0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$144.42
Aprire:
$142.61
Volume 24 ore:
5.64M
Relative Volume:
1.48
Capitalizzazione di mercato:
$105.29B
Reddito:
$13.88B
Utile/perdita netta:
$5.40B
Rapporto P/E:
40.97
EPS:
3.4868
Flusso di cassa netto:
$2.02B
1 W Prestazione:
-5.83%
1M Prestazione:
-15.20%
6M Prestazione:
+3.95%
1 anno Prestazione:
-14.48%
Intervallo 1D:
$142.45
$145.90
Intervallo di 1 settimana:
$142.45
$152.25
Portata 52W:
$115.66
$200.96
Blackstone Inc Stock (BX) Company Profile
Nome
Blackstone Inc
Settore
Industria
Telefono
(212) 583-5000
Indirizzo
345 PARK AVENUE, NEW YORK, NY
Confronta BX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BX
Blackstone Inc
|
142.85 | 113.04B | 13.88B | 5.40B | 2.02B | 3.4868 |
|
BLK
Blackrock Inc
|
1,059.91 | 165.78B | 23.53B | 6.37B | 4.02B | 38.90 |
|
KKR
Kkr Co Inc
|
118.29 | 104.80B | 17.85B | 4.86B | 6.64B | 2.0851 |
|
BAM
Brookfield Asset Management Ltd
|
53.89 | 87.69B | 2.46B | 1.41B | 992.79M | 1.4814 |
|
BN
Brookfield Corporation
|
45.54 | 103.19B | 77.46B | 2.89B | -1.18B | 0.2991 |
Blackstone Inc Stock (BX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-03 | Iniziato | BMO Capital Markets | Outperform |
| 2025-04-08 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-10-09 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-09-12 | Iniziato | Wells Fargo | Overweight |
| 2024-08-27 | Iniziato | Redburn Atlantic | Neutral |
| 2024-04-02 | Downgrade | UBS | Buy → Neutral |
| 2024-01-19 | Downgrade | Citigroup | Buy → Neutral |
| 2024-01-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Iniziato | TD Cowen | Market Perform |
| 2024-01-03 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-20 | Ripresa | Piper Sandler | Overweight |
| 2023-12-06 | Ripresa | BMO Capital Markets | Market Perform |
| 2023-10-06 | Iniziato | HSBC Securities | Hold |
| 2023-10-05 | Iniziato | Wolfe Research | Peer Perform |
| 2023-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-05-19 | Iniziato | Citigroup | Buy |
| 2023-04-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-11 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-12-02 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-11-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-10-19 | Iniziato | Credit Suisse | Neutral |
| 2022-10-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-31 | Iniziato | Barclays | Overweight |
| 2022-07-25 | Downgrade | Keefe Bruyette | Outperform → Mkt Perform |
| 2022-04-07 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-16 | Ripresa | BofA Securities | Buy |
| 2021-12-16 | Iniziato | Wells Fargo | Equal Weight |
| 2021-11-04 | Ripresa | BofA Securities | Buy |
| 2021-08-11 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-03-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-14 | Iniziato | Piper Sandler | Overweight |
| 2020-10-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-25 | Iniziato | UBS | Buy |
| 2020-06-08 | Downgrade | Citigroup | Buy → Neutral |
| 2019-10-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-10-08 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-10-01 | Iniziato | Wells Fargo | Outperform |
| 2019-09-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2019-09-23 | Reiterato | BofA/Merrill | Buy |
| 2019-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-05 | Iniziato | Barclays | Overweight |
| 2019-07-08 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-01-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2016-03-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2016-02-02 | Reiterato | Argus | Buy |
| 2016-01-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-01-08 | Reiterato | Deutsche Bank | Buy |
| 2015-12-08 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-11-23 | Iniziato | JP Morgan | Neutral |
| 2015-10-27 | Reiterato | Argus | Buy |
Mostra tutto
Blackstone Inc Borsa (BX) Ultime notizie
Merck and Blackstone Partner in $700 Million Deal to Advance TROP2-Targeting Cancer Therapy - geneonline.com
Blackstone’s alternative narratives - Financial Times
Blackstone Funding Deal Might Change the Case For Investing In Merck (MRK) - simplywall.st
Blackstone president says businesses should worry about AI disruption - Nikkei Asia
Private Equity Must Sell More Assets — at Whatever Price - Bloomberg.com
Blackstone-Backed Food Sanitation Cleaner Inks Workout Deal - Bloomberg.com
Blackstone scores rare premium in Boston office building sale - The Business Times
Blackstone Scores Rare Premium in Boston Office Building Sale - Bloomberg.com
Despite payout cut, Blackstone BDC 'expects' a strong November, president Jonathan Gray says - InvestmentNews
Sector Update: Health Care Stocks Rise Late Afternoon - MarketScreener
Private Credit Dealmakers Face Years of Heavy Lifting in Japan - Bloomberg.com
The Every Company's Series D, Apollo's $6.5b wind farm bet, and Blackstone invests in Merck - Axios
Key facts: Blackstone reports $54.2B inflows; to acquire Hologic for $18.3B; buys stake in TriMas for $1.45B - TradingView
SEI gatekeepers drop T. Rowe for Blackstone on $3.2bn high-yield strategy - Citywire
Merck & Co. secures $700M from Blackstone to fund lead ADC sac-TMT - FirstWord Pharma
Merck Entering $700 Million R&D Funding Agreement With Blackstone Life Sciences - Pulse 2.0
Blackstone $1.45bn CMBS oversubscribed - GlobalCapital
Royalty Pharma Buys Royalty Interest in Alnylam Pharmaceuticals' Amvuttra From Blackstone Life Sciences for $310 Million - MarketScreener
Bain Lines Up $3.1 Billion Private Loan for Service Logic Buy - Bloomberg.com
Merck & Co Receive $700 Million From Blackstone to Boost Cancer Drug Development - USA Herald
Blackstone Injecting $700M Into Merck Cancer Therapy - Law360
Merck secures $700 million funding from Blackstone to develop cancer therapy - Reuters
Earnings call transcript: Black Stone Minerals Q3 2025 beats expectations - Investing.com
Private equity powering AI boom at public cost - Private Equity Stakeholder Project PESP
Packaging firm TriMas to sell aerospace arm for $1.45 billion under Barington pressure - Reuters
Merck & Blackstone Enter Research and Development Funding Agreement - Contract Pharma
Blackstone-backed Nexus Select Trust eyes multiple mall acquisitions - livemint.com
Merck strikes financing agreement with Blackstone - MarketScreener
Merck to Receive $700 Million From Blackstone Unit to Support Experimental Cancer Drug Development - MarketScreener
Merck writes tale of 2 checks, bagging $700M from Blackstone and spending $150M to regain asset - Fierce Biotech
Merck (MRK) Secures $700M from Blackstone for Cancer Therapy Dev - GuruFocus
Merck clinches $700 million from Blackstone to develop ADC for cancer - PharmaLive
TriMas Enters Into Agreement to Sell TriMas Aerospace for $1.45 Billion - Yahoo Finance
Merck to receive $700M from Blackstone to develop cancer therapy - MSN
Merck inks $700M deal with Blackstone for cancer drug (MRK) - Seeking Alpha
Blackstone (BX) Invests in Merck's Cancer Treatment Development - GuruFocus
Corton Capital Inc. Invests $327,000 in Blackstone Inc. $BX - MarketBeat
Blackstone to pay Merck $700M to fund development of antibody-drug conjugate - Endpoints News
Wellington Shields Capital Management LLC Grows Stake in Blackstone Inc. $BX - MarketBeat
Royalty Pharma (NASDAQ: RPRX) acquires 1% AMVUTTRA royalty for $310M from Blackstone - Stock Titan
Merck secures $700 million from Blackstone to fund cancer drug development - Investing.com
Blackstone pays Merck $700M to buy into ADC drug royalties - Yahoo Finance
Merck, Blackstone Life Sciences sign R&D funding deal for sacituzumab tirumotecan (sac-TMT) - MarketScreener
Merck and Blackstone enter research agreement to develop cancer therapy for $700 million - MarketScreener
Ex-Blackstone, Partners Group Execs Raise $1.1B for APAC Real Estate Secondaries - Mingtiandi
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) - MarketScreener
Merck receives $700 million from Blackstone for cancer drug development - StreetInsider
Bank of New York Mellon Corp Sells 288,843 Shares of Blackstone Inc. $BX - MarketBeat
FERC urged to reject Blackstone’s New Mexico utility takeover - Southwest Ledger
Royalty Pharma acquires royalty stake in Alnylam’s Amvuttra from Blackstone for $310m - pehub.com
Blackstone Inc. $BX Shares Sold by Freestone Capital Holdings LLC - MarketBeat
Blackstone Inc Azioni (BX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.56%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):